- Home
- CATX vs THW Comparison
CATX vs THW Comparison
Compare CATX & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATX | THW |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.4M | 513.9M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CATX | THW |
|---|---|---|
| Price | $4.96 | $12.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 139.8K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $9.80 |
| 52 Week High | $6.16 | $13.19 |
Technical Indicators
Market Signals| Indicator | CATX | THW |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 34.36 |
| Support Level | $3.24 | $11.80 |
| Resistance Level | $5.39 | $12.13 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 33.21 | 13.50 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About THW abrdn World Healthcare Fund Shares of Beneficial Interest
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.